pharmacoepidemiology

Abrahami, D., D'Andrea, E., Yin, H., Kim, S. C., Paik, J. M., Wexler, D., et al. (2023). Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes Obes Metab. http://doi.org/10.1111/dom.15196
van Hulten, V., Driessen, J. H. M., Starup-Linde, J. K., Al-Mashhadi, Z. K., Viggers, R., Klungel, O. H., et al. (2023). The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus. Diabetes Obes Metab. http://doi.org/10.1111/dom.15220
Ashworth, J., Bajpai, R., Muller, S., Bailey, J., Helliwell, T., Harrisson, S. A., et al. (2023). Trends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study. The Lancet Regional Health - Europe, 27, 100579. http://doi.org/https://doi.org/10.1016/j.lanepe.2022.100579
Jani, M., Yimer, B. B., Selby, D., Lunt, M., Nenadic, G., & Dixon, W. G. (2023). "Take up to eight tablets per day": Incorporating free-text medication instructions into a transparent and reproducible process for preparing drug exposure data for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5595
Bidulka, P., Mathur, R., Lugo-Palacios, D. G., O'Neill, S., Basu, A., Silverwood, R. J., et al. (2022). Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment in people with type 2 diabetes in England: a cross-sectional study. Diabetes Obes Metab. http://doi.org/10.1111/dom.14874
Eroglu, T. E., Coronel, R., Zuurbier, C. J., Blom, M., de Boer, A., & Souverein, P. C. (2022). Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus. Eur Heart J Cardiovasc Pharmacother. http://doi.org/10.1093/ehjcvp/pvac043
Persson, R., Hagberg, K. W., Vasilakis-Scaramozza, C., Yelland, E., Williams, T., Myles, P., & Jick, S. S. (2022). Presence of Codes for Indication for Use in Clinical Practice Research Datalink Aurum: An Assessment of Benign Prostatic Hyperplasia Treatments. Clin Epidemiol, 14, 641-652. http://doi.org/10.2147/clep.s360843
van Sloten, T. T., Souverein, P. C., Stehouwer, C. D., & Driessen, J. H. (2022). Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and risk of depression among older people with hypertension. J Psychopharmacol, 2698811221082470. http://doi.org/10.1177/02698811221082470
Penner, L. S., Gavan, S. P., Ashcroft, D. M., Peek, N., & Elliott, R. A. (2022). Does co-prescribing non-steroidal anti-inflammatory drugs and oral anticoagulants increase the risk of major bleeding, stroke and systemic embolism?. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.15371
Pradhan, R., Patorno, E., Tesfaye, H., Schneeweiss, S., Yin, H., Franklin, J., et al. (2022). Glucagon-Like Peptide-1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: Multisite Population-Based Cohort Study. Am J Epidemiol. http://doi.org/10.1093/aje/kwac021